CD19/CD22 Bispecific CAR-T Cell Therapy(Beijing Tongren Hospital)

N/A

Report date: 2023/11/01 20:08:59

Base Information

Drug NameCD19/CD22 Bispecific CAR-T Cell Therapy(Beijing Tongren Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19Anti-CD22T lymphocyte replacements
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Tongren Hospital, Cmu
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Tongren Hospital, Cmu
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A